IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) - Total Assets
Based on the latest financial reports, IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) holds total assets worth €6.94 Billion EUR (≈ $8.11 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) net assets for net asset value and shareholders' equity analysis.
IPSEN SA SP.ADR 1/4/ EO 1 - Total Assets Trend (2021–2025)
This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's total assets have evolved over time, based on quarterly financial data. Check I7G0 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
IPSEN SA SP.ADR 1/4/ EO 1 - Asset Composition Analysis
Current Asset Composition (December 2025)
IPSEN SA SP.ADR 1/4/ EO 1's total assets of €6.94 Billion consist of 40.7% current assets and 59.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 22.0% |
| Accounts Receivable | €786.80 Million | 11.3% |
| Inventory | €240.90 Million | 3.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.29 Billion | 33.0% |
| Goodwill | €633.80 Million | 9.1% |
Asset Composition Trend (2021–2025)
This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IPSEN SA SP.ADR 1/4/ EO 1's current assets represent 40.7% of total assets in 2025, an increase from 39.2% in 2021.
- Cash Position: Cash and equivalents constituted 22.0% of total assets in 2025, up from 16.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 41.0% of total assets, an increase from 39.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.0% of total assets.
IPSEN SA SP.ADR 1/4/ EO 1 Competitors by Total Assets
Key competitors of IPSEN SA SP.ADR 1/4/ EO 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
IPSEN SA SP.ADR 1/4/ EO 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 1.34 | 1.34 |
| Quick Ratio | 1.79 | 1.15 | 1.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.38 Billion | €515.80 Million | €515.80 Million |
IPSEN SA SP.ADR 1/4/ EO 1 - Advanced Valuation Insights
This section examines the relationship between IPSEN SA SP.ADR 1/4/ EO 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.18 |
| Latest Market Cap to Assets Ratio | 1.86 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | €6.94 Billion |
| Market Capitalization | $12.92 Billion USD |
Valuation Analysis
Above Book Valuation: The market values IPSEN SA SP.ADR 1/4/ EO 1's assets above their book value (1.86x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: IPSEN SA SP.ADR 1/4/ EO 1's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual total assets of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €6.94 Billion ≈ $8.11 Billion |
+7.75% |
| 2024-12-31 | €6.44 Billion ≈ $7.53 Billion |
+1.84% |
| 2023-12-31 | €6.32 Billion ≈ $7.39 Billion |
+12.62% |
| 2022-12-31 | €5.61 Billion ≈ $6.56 Billion |
+12.51% |
| 2021-12-31 | €4.99 Billion ≈ $5.83 Billion |
-- |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more